Use of Immunotherapy in Lung Adenocarcinoma
DOI:
https://doi.org/10.58445/rars.1099Keywords:
Immunotherapy, Adenocarcinoma, LungsAbstract
This paper discusses the most common lung cancer amongst cased worldwide: lung adenocarcinoma. It explores current research being conducted when exploring possibly biomarkers that could indicate tumor formation or therapies for personalized treatments.
References
Antoni Ribas; Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov 1 September 2015; 5 (9): 915–919. https://doi.org/10.1158/2159-8290.CD-15-0563
Sandlin CW, Gu S, Xu J, Deshpande C, Feldman MD, Good MC. Epithelial cell size dysregulation in human lung adenocarcinoma. PLoS One. 2022 Oct 6;17(10):e0274091. doi: 10.1371/journal.pone.0274091. PMID: 36201559; PMCID: PMC9536599.
L Succony, DM Rassl, AP Barker, FM McCaughan, RC Rintoul, Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies, Cancer Treatment Reviews, Volume 99, 2021, 102237, ISSN 0305-7372, https://doi.org/10.1016/j.ctrv.2021.102237.
Inamura K. Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. International Journal of Molecular Sciences. 2018; 19(4):1259. https://doi.org/10.3390/ijms19041259
D Jingsi, L Bingjie, L Dan , Z Qinghua, H Depei; Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing; Frontiers in Pharmacology; 2019 Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00230
Rendon A, Rayi A. Nivolumab. [Updated 2022 Dec 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567801/
Additional Files
Posted
Categories
License
Copyright (c) 2024 S. Kaarthiga
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.